Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder

S. D. Kaupp-Roberts, G. Yadegarfar, E. Friend, C. M. O'Donnell, J. W. Valle, C. Byrne, I. Bahar, M. Finch-Jones, R. Gillmore, C. D. Johnson, S. P. Pereira, J. K. Wiggers, M. Pinto, B. Al-Sarireh, J. K. Ramage

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: There is no specific quality of life (QoL) measurement tool to quantify QoL in patients with biliary tract cancer. Quality of life measurement is an increasingly crucial trial end point and is now being incorporated into clinical practice. Methods: This International Multicentre Phase IV Validation Study assessed the QLQ-BIL21 module in 172 patients with cholangiocarcinoma and 91 patients with cancer of the gallbladder. Patients completed the questionnaire at baseline pretherapy and subsequently at 2 months. Following this, the psychometric properties of reliability, validity, scale structure and responsiveness to change were analysed. Results: Analysis of the QLQ-BIL21 scales showed appropriate reliability with Cronbach's α-coefficients >0.70 for all scales overall. Intraclass correlations exceeded 0.80 for all scales. Convergent validity >0.40 was demonstrated for all items within scales, and discriminant validity was confirmed with values <0.70 for all scales compared with each other. Scale scores changed in accordance with Karnofsky performance status and in response to clinical change. Conclusions: The QLQ-BIL21 is a valid tool for the assessment of QoL in patients with cholangiocarcinoma and cancer of the gallbladder.

Original languageEnglish
Pages (from-to)1032-1038
Number of pages7
JournalBritish Journal of Cancer
Volume115
Issue number9
DOIs
Publication statusPublished - Oct 25 2016

Fingerprint

Gallbladder Neoplasms
Cholangiocarcinoma
Quality of Life
Biliary Tract Neoplasms
Karnofsky Performance Status
Validation Studies
Psychometrics
Reproducibility of Results
Surveys and Questionnaires

Keywords

  • cholangiocarcinoma
  • EORTC
  • gallbladder cancer
  • hepatobiliary cancer
  • PROM
  • QLQ-BIL21
  • quality of life

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Kaupp-Roberts, S. D., Yadegarfar, G., Friend, E., O'Donnell, C. M., Valle, J. W., Byrne, C., ... Ramage, J. K. (2016). Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. British Journal of Cancer, 115(9), 1032-1038. https://doi.org/10.1038/bjc.2016.284

Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. / Kaupp-Roberts, S. D.; Yadegarfar, G.; Friend, E.; O'Donnell, C. M.; Valle, J. W.; Byrne, C.; Bahar, I.; Finch-Jones, M.; Gillmore, R.; Johnson, C. D.; Pereira, S. P.; Wiggers, J. K.; Pinto, M.; Al-Sarireh, B.; Ramage, J. K.

In: British Journal of Cancer, Vol. 115, No. 9, 25.10.2016, p. 1032-1038.

Research output: Contribution to journalArticle

Kaupp-Roberts, SD, Yadegarfar, G, Friend, E, O'Donnell, CM, Valle, JW, Byrne, C, Bahar, I, Finch-Jones, M, Gillmore, R, Johnson, CD, Pereira, SP, Wiggers, JK, Pinto, M, Al-Sarireh, B & Ramage, JK 2016, 'Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder', British Journal of Cancer, vol. 115, no. 9, pp. 1032-1038. https://doi.org/10.1038/bjc.2016.284
Kaupp-Roberts, S. D. ; Yadegarfar, G. ; Friend, E. ; O'Donnell, C. M. ; Valle, J. W. ; Byrne, C. ; Bahar, I. ; Finch-Jones, M. ; Gillmore, R. ; Johnson, C. D. ; Pereira, S. P. ; Wiggers, J. K. ; Pinto, M. ; Al-Sarireh, B. ; Ramage, J. K. / Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder. In: British Journal of Cancer. 2016 ; Vol. 115, No. 9. pp. 1032-1038.
@article{2e6acca4f67441d7ba978309ae8e4707,
title = "Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder",
abstract = "Background: There is no specific quality of life (QoL) measurement tool to quantify QoL in patients with biliary tract cancer. Quality of life measurement is an increasingly crucial trial end point and is now being incorporated into clinical practice. Methods: This International Multicentre Phase IV Validation Study assessed the QLQ-BIL21 module in 172 patients with cholangiocarcinoma and 91 patients with cancer of the gallbladder. Patients completed the questionnaire at baseline pretherapy and subsequently at 2 months. Following this, the psychometric properties of reliability, validity, scale structure and responsiveness to change were analysed. Results: Analysis of the QLQ-BIL21 scales showed appropriate reliability with Cronbach's α-coefficients >0.70 for all scales overall. Intraclass correlations exceeded 0.80 for all scales. Convergent validity >0.40 was demonstrated for all items within scales, and discriminant validity was confirmed with values <0.70 for all scales compared with each other. Scale scores changed in accordance with Karnofsky performance status and in response to clinical change. Conclusions: The QLQ-BIL21 is a valid tool for the assessment of QoL in patients with cholangiocarcinoma and cancer of the gallbladder.",
keywords = "cholangiocarcinoma, EORTC, gallbladder cancer, hepatobiliary cancer, PROM, QLQ-BIL21, quality of life",
author = "Kaupp-Roberts, {S. D.} and G. Yadegarfar and E. Friend and O'Donnell, {C. M.} and Valle, {J. W.} and C. Byrne and I. Bahar and M. Finch-Jones and R. Gillmore and Johnson, {C. D.} and Pereira, {S. P.} and Wiggers, {J. K.} and M. Pinto and B. Al-Sarireh and Ramage, {J. K.}",
year = "2016",
month = "10",
day = "25",
doi = "10.1038/bjc.2016.284",
language = "English",
volume = "115",
pages = "1032--1038",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Validation of the EORTC QLQ-BIL21 questionnaire for measuring quality of life in patients with cholangiocarcinoma and cancer of the gallbladder

AU - Kaupp-Roberts, S. D.

AU - Yadegarfar, G.

AU - Friend, E.

AU - O'Donnell, C. M.

AU - Valle, J. W.

AU - Byrne, C.

AU - Bahar, I.

AU - Finch-Jones, M.

AU - Gillmore, R.

AU - Johnson, C. D.

AU - Pereira, S. P.

AU - Wiggers, J. K.

AU - Pinto, M.

AU - Al-Sarireh, B.

AU - Ramage, J. K.

PY - 2016/10/25

Y1 - 2016/10/25

N2 - Background: There is no specific quality of life (QoL) measurement tool to quantify QoL in patients with biliary tract cancer. Quality of life measurement is an increasingly crucial trial end point and is now being incorporated into clinical practice. Methods: This International Multicentre Phase IV Validation Study assessed the QLQ-BIL21 module in 172 patients with cholangiocarcinoma and 91 patients with cancer of the gallbladder. Patients completed the questionnaire at baseline pretherapy and subsequently at 2 months. Following this, the psychometric properties of reliability, validity, scale structure and responsiveness to change were analysed. Results: Analysis of the QLQ-BIL21 scales showed appropriate reliability with Cronbach's α-coefficients >0.70 for all scales overall. Intraclass correlations exceeded 0.80 for all scales. Convergent validity >0.40 was demonstrated for all items within scales, and discriminant validity was confirmed with values <0.70 for all scales compared with each other. Scale scores changed in accordance with Karnofsky performance status and in response to clinical change. Conclusions: The QLQ-BIL21 is a valid tool for the assessment of QoL in patients with cholangiocarcinoma and cancer of the gallbladder.

AB - Background: There is no specific quality of life (QoL) measurement tool to quantify QoL in patients with biliary tract cancer. Quality of life measurement is an increasingly crucial trial end point and is now being incorporated into clinical practice. Methods: This International Multicentre Phase IV Validation Study assessed the QLQ-BIL21 module in 172 patients with cholangiocarcinoma and 91 patients with cancer of the gallbladder. Patients completed the questionnaire at baseline pretherapy and subsequently at 2 months. Following this, the psychometric properties of reliability, validity, scale structure and responsiveness to change were analysed. Results: Analysis of the QLQ-BIL21 scales showed appropriate reliability with Cronbach's α-coefficients >0.70 for all scales overall. Intraclass correlations exceeded 0.80 for all scales. Convergent validity >0.40 was demonstrated for all items within scales, and discriminant validity was confirmed with values <0.70 for all scales compared with each other. Scale scores changed in accordance with Karnofsky performance status and in response to clinical change. Conclusions: The QLQ-BIL21 is a valid tool for the assessment of QoL in patients with cholangiocarcinoma and cancer of the gallbladder.

KW - cholangiocarcinoma

KW - EORTC

KW - gallbladder cancer

KW - hepatobiliary cancer

KW - PROM

KW - QLQ-BIL21

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=84988723540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988723540&partnerID=8YFLogxK

U2 - 10.1038/bjc.2016.284

DO - 10.1038/bjc.2016.284

M3 - Article

AN - SCOPUS:84988723540

VL - 115

SP - 1032

EP - 1038

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 9

ER -